Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A randomized trial shows that a low-cost, accessible, walking-based intervention reduced low-back-pain recurrence, and could offer a scalable approach to tackling this common condition.
Alzheimer’s disease can be treated by targeting amyloid-β plaques and diagnosed in vivo by biomarkers, prompting the revision of criteria for the diagnosis and staging of this disease.
A multi-modal analysis of pre-metastatic liver biopsies from patients with localized pancreatic cancer with a minimum of 3 years of follow-up shows that immunological, proliferative and metabolomic features distinguish patients who develop metastases from disease-free survivors and can be used to predict outcomes.
In this phase 3 trial, first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with anti-PD-1 finotonlimab plus cisplatin plus 5-fluorouracil (C5F) prolonged overall survival compared with placebo plus C5F.
In a phase 1 trial in a single patient with hereditary spastic paraplegia type 50, a personalized AAV9-based gene therapy was developed within 3 years from diagnosis and was well tolerated, showing preliminary evidence of disease stabilization.
When tested across tasks, diseases and imaging modalities, the performance of AI models depends on encoding of demographic shortcuts, and correcting for them decreases their ability to generalize in new populations.
In a randomized phase 1 trial, the addition of a live Clostridium species-containing product to a tyrosine kinase inhibitor and anti-programmed cell death protein 1 treatment combination did not increase bacterial abundance of Bifidobacterium spp. but enhanced clinical responses in participants with metastatic renal cell carcinoma.
Circuitry-based neuroimaging analyses can enhance our understanding of abnormal brain functioning in patients with major depressive disorder and other psychiatric conditions — but their utility for guiding treatment selection is less certain.
A phase 3 trial establishes 177Lu-dotatate plus long-acting octreotide as a new first-line treatment for patients with high-grade gastroenteropancreatic neuroendocrine tumors.
As diabetes technology evolves, implementation of equitable, sustainable, remote patient monitoring will ensure that this technology is accessible to everyone with type 1 diabetes — but strategies to address the burden of data collection and review are crucial.
A randomized controlled trial performed in a screen-and-treat program in Zambia found that a portable, battery-operated thermal ablation device was not inferior to cryotherapy and electrosurgical excision in cervical precancer treatment.
Using an international collection of population-based microbiome studies of participants in the MicroCardio Consortium, a cross-cohort meta-analysis identified several phylogenetically diverse, species- and strain-level microbial features as well as community-level functional shifts encompassing diverse pathways to type 2 diabetes.
A combined-ancestry GWAS of diabetic retinopathy, comprising 68,169 cases and 129,188 controls, revealed nine previously unreported loci associated with the condition, including an evolutionarily adaptive genetic variant alongside a potential functional mechanism that influences racial disparities in diabetes complications among individuals of non-Hispanic African ancestry.
Fortunate Machingura heads CeSHHAR Zimbabwe’s Climate, Environment, and Health Department and is also a lecturer at the Liverpool School of Tropical Medicine. She describes her pivot from HIV research to another crucial challenge facing Africa: climate change.
In a pre-specified analysis of the FLOW trial, the use of an SGLT2 inhibitor did not impact the overall benefits of of semaglutide on kidney and cardiovascular outcomes in participants with type 2 diabetes and chronic kidney disease
A phase 2 dose-finding study of an extended-release tablet formulation of ketamine in patients with treatment-resistant depression shows that this formulation overcomes many of the limitations associated with the use of intravenous or intranasal ketamine formulations.